Characteristics and Determinants of Partial Remission in Children with Type 1 Diabetes Using the Insulin-dose-adjusted A1C Definition
Overview
Authors
Affiliations
To evaluate the characteristics and determinants of partial remission (PR) in Belgian children with type 1 diabetes (T1D), we analyzed records of 242 children from our center. Clinical and biological features were collected at diagnosis and during follow-up. PR was defined using the insulin-dose-adjusted A1C definition. PR occurred in 56.2% of patients and lasted 9.2 months (0.5 to 56.6). 25.6% of patients entered T1D with DKA, which correlated with lower PR incidence (17.6% versus 82.3% when no DKA). In our population, lower A1C levels at diagnosis were associated with higher PR incidence and in young children (0-4 years) initial A1C levels negatively correlated with longer PR. Early A1C levels were predictive of PR duration since 34% of patients had long PRs (>1 year) when A1C levels were ≤ 6% after 3 months whereas incidence of long PR decreased with higher A1Cs. C-peptide levels were higher in patients entering PR and remained higher until 3 years after diagnosis. Initial antibody titers did not influence PR except for anti-IA2 titers that correlated with A1C levels after 2 years. Presence of 2 versus 1 anti-islet antibodies correlated with shorter PR. PR duration did not influence occurrence of severe hypoglycemia or diabetes-related complications but was associated with lower A1C levels after 18 months. We show that, at diagnosis of T1D, parameters associated with β-cell mass reserve (A1C, C-peptide, and DKA) correlate with the occurrence of PR, which affects post-PR A1C levels. Further research is needed to determine the long-term significance of PR.
Cimbek E, Beyhun N, Karaguzel G Eur J Pediatr. 2025; 184(3):219.
PMID: 40025382 PMC: 11872750. DOI: 10.1007/s00431-025-06046-3.
Flotynska J, Naskret D, Niedzwiecki P, Grzelka-Wozniak A, Pypec A, Kaczmarek A Clin Med Insights Endocrinol Diabetes. 2024; 17:11795514241244872.
PMID: 38628617 PMC: 11020723. DOI: 10.1177/11795514241244872.
Felton J, Redondo M, Oram R, Speake C, Long S, Onengut-Gumuscu S Commun Med (Lond). 2024; 4(1):66.
PMID: 38582818 PMC: 10998887. DOI: 10.1038/s43856-024-00478-y.
Kennedy E, Hawkes C Children (Basel). 2024; 11(2).
PMID: 38397298 PMC: 10887271. DOI: 10.3390/children11020186.
Honeymoon phase in type 1 diabetes mellitus: A window of opportunity for diabetes reversal?.
Mittal M, Porchezhian P, Kapoor N World J Clin Cases. 2024; 12(1):9-14.
PMID: 38292619 PMC: 10824181. DOI: 10.12998/wjcc.v12.i1.9.